Immediate	immediate	O	O
allergic	allergic	O	B_disease
reactions	reactions	O	I_disease
to	to	O	O
amoxicillin	amoxicillin	S_chemicals	O
.	.	O	O

A	a	O	O
large	large	O	O
group	group	O	O
of	of	O	O
patients	patients	O	O
with	with	O	O
suspected	suspected	O	O
allergic	allergic	O	B_disease
reactions	reactions	O	I_disease
to	to	O	O
beta-lactam	beta-lactam	S_chemicals	O
antibiotics	antibiotics	S_chemicals	O
was	was	O	O
evaluated	evaluated	O	O
.	.	O	O

A	a	O	O
detailed	detailed	O	O
clinical	clinical	O	O
history	history	O	O
,	,	O	O
together	together	O	O
with	with	O	O
skin	skin	O	O
tests	tests	O	O
,	,	O	O
RAST	rast	O	O
(	(	O	O
radioallergosorbent	radioallergosorbent	O	O
test	test	O	O
)	)	O	O
,	,	O	O
and	and	O	O
controlled	controlled	O	O
challenge	challenge	O	O
tests	tests	O	O
,	,	O	O
was	was	O	O
used	used	O	O
to	to	O	O
establish	establish	O	O
whether	whether	O	O
patients	patients	O	O
allergic	allergic	O	O
to	to	O	O
beta-lactam	beta-lactam	S_chemicals	O
antibiotics	antibiotics	S_chemicals	O
had	had	O	O
selective	selective	O	O
immediate	immediate	O	O
allergic	allergic	O	O
responses	responses	O	O
to	to	O	O
amoxicillin	amoxicillin	S_chemicals	O
(	(	O	O
AX	ax	O	O
)	)	O	O
or	or	O	O
were	were	O	O
cross-reacting	cross-reacting	O	O
with	with	O	O
other	other	O	O
penicillin	penicillin	O	O
derivatives	derivatives	O	O
.	.	O	O

Skin	skin	O	O
tests	tests	O	O
were	were	O	O
performed	performed	O	O
with	with	O	O
benzylpenicilloyl-poly-L-lysine	benzylpenicilloyl-poly-l-lysine	O	O
(	(	O	O
BPO-PLL	bpo-pll	O	O
)	)	O	O
,	,	O	O
benzylpenicilloate	benzylpenicilloate	O	O
,	,	O	O
benzylpenicillin	benzylpenicillin	S_chemicals	O
(	(	O	O
PG	pg	S_chemicals	O
)	)	O	O
,	,	O	O
ampicillin	ampicillin	S_chemicals	O
(	(	O	O
AMP	amp	S_chemicals	O
)	)	O	O
,	,	O	O
and	and	O	O
AX	ax	O	O
.	.	O	O

RAST	rast	O	O
for	for	O	O
BPO-PLL	bpo-pll	O	O
and	and	O	O
AX-PLL	ax-pll	O	O
was	was	O	O
done	done	O	O
.	.	O	O

When	when	O	O
both	both	O	O
skin	skin	O	O
test	test	O	O
and	and	O	O
RAST	rast	O	O
for	for	O	O
BPO	bpo	O	O
were	were	O	O
negative	negative	O	O
,	,	O	O
single-blind	single-blind	O	O
,	,	O	O
placebo-controlled	placebo-controlled	O	O
challenge	challenge	O	O
tests	tests	O	O
were	were	O	O
done	done	O	O
to	to	O	O
ensure	ensure	O	O
tolerance	tolerance	O	O
of	of	O	O
PG	pg	S_chemicals	O
or	or	O	O
sensitivity	sensitivity	O	O
to	to	O	O
AX	ax	O	O
.	.	O	O

A	a	O	O
total	total	O	O
of	of	O	O
177	177	O	O
patients	patients	O	O
were	were	O	O
diagnosed	diagnosed	O	O
as	as	O	O
allergic	allergic	O	O
to	to	O	O
beta-lactam	beta-lactam	S_chemicals	O
antibiotics	antibiotics	S_chemicals	O
.	.	O	O

We	we	O	O
selected	selected	O	O
the	the	O	O
54	54	O	O
(	(	O	O
30.5	30.5	O	O
%	%	O	O
)	)	O	O
cases	cases	O	O
of	of	O	O
immediate	immediate	O	O
AX	ax	O	O
allergy	allergy	O	S_disease
with	with	O	O
good	good	O	O
tolerance	tolerance	O	O
of	of	O	O
PG	pg	S_chemicals	O
.	.	O	O

Anaphylaxis	anaphylaxis	O	O
was	was	O	O
seen	seen	O	O
in	in	O	O
37	37	O	O
patients	patients	O	O
(	(	O	O
69	69	O	O
%	%	O	O
)	)	O	O
,	,	O	O
the	the	O	O
other	other	O	O
17	17	O	O
(	(	O	O
31	31	O	O
%	%	O	O
)	)	O	O
having	having	O	O
urticaria	urticaria	O	S_disease
and/or	and/or	O	O
angioedema	angioedema	O	S_disease
.	.	O	O

All	all	O	O
the	the	O	O
patients	patients	O	O
were	were	O	O
skin	skin	O	O
test	test	O	O
negative	negative	O	O
to	to	O	O
BPO	bpo	O	O
;	;	O	O
49	49	O	O
of	of	O	O
51	51	O	O
(	(	O	O
96	96	O	O
%	%	O	O
)	)	O	O
were	were	O	O
also	also	O	O
negative	negative	O	O
to	to	O	O
MDM	mdm	O	O
,	,	O	O
and	and	O	O
44	44	O	O
of	of	O	O
46	46	O	O
(	(	O	O
96	96	O	O
%	%	O	O
)	)	O	O
to	to	O	O
PG	pg	S_chemicals	O
.	.	O	O

Skin	skin	O	O
tests	tests	O	O
with	with	O	O
AX	ax	O	O
were	were	O	O
positive	positive	O	O
in	in	O	O
34	34	O	O
(	(	O	O
63	63	O	O
%	%	O	O
)	)	O	O
patients	patients	O	O
.	.	O	O

RAST	rast	O	O
was	was	O	O
positive	positive	O	O
for	for	O	O
AX	ax	O	O
in	in	O	O
22	22	O	O
patients	patients	O	O
(	(	O	O
41	41	O	O
%	%	O	O
)	)	O	O
and	and	O	O
to	to	O	O
BPO	bpo	O	O
in	in	O	O
just	just	O	O
5	5	O	O
(	(	O	O
9	9	O	O
%	%	O	O
)	)	O	O
.	.	O	O

None	none	O	O
of	of	O	O
the	the	O	O
sera	sera	O	O
with	with	O	O
negative	negative	O	O
RAST	rast	O	O
for	for	O	O
AX	ax	O	O
were	were	O	O
positive	positive	O	O
to	to	O	O
BPO	bpo	O	O
.	.	O	O

Challenge	challenge	O	O
tests	tests	O	O
with	with	O	O
AX	ax	O	O
were	were	O	O
performed	performed	O	O
in	in	O	O
23	23	O	O
subjects	subjects	O	O
(	(	O	O
43	43	O	O
%	%	O	O
)	)	O	O
to	to	O	O
establish	establish	O	O
the	the	O	O
diagnosis	diagnosis	O	O
of	of	O	O
immediate	immediate	O	O
allergic	allergic	O	B_disease
reaction	reaction	O	I_disease
to	to	O	O
AX	ax	O	O
,	,	O	O
and	and	O	O
in	in	O	O
15	15	O	O
cases	cases	O	O
(	(	O	O
28	28	O	O
%	%	O	O
)	)	O	O
both	both	O	O
skin	skin	O	O
test	test	O	O
and	and	O	O
RAST	rast	O	O
for	for	O	O
AX	ax	O	O
were	were	O	O
negative	negative	O	O
.	.	O	O

PG	pg	S_chemicals	O
was	was	O	O
well	well	O	O
tolerated	tolerated	O	O
by	by	O	O
all	all	O	O
54	54	O	O
patients	patients	O	O
.	.	O	O

We	we	O	O
describe	describe	O	O
the	the	O	O
largest	largest	O	O
group	group	O	O
of	of	O	O
AX-allergic	ax-allergic	O	O
patients	patients	O	O
who	who	O	O
have	have	O	O
tolerated	tolerated	O	O
PG	pg	S_chemicals	O
reported	reported	O	O
so	so	O	O
far	far	O	O
.	.	O	O

Diagnosis	diagnosis	O	O
of	of	O	O
these	these	O	O
patients	patients	O	O
can	can	O	O
be	be	O	O
achieved	achieved	O	O
only	only	O	O
if	if	O	O
specific	specific	O	O
AX-related	ax-related	O	O
reagents	reagents	S_chemicals	O
are	are	O	O
employed	employed	O	O
.	.	O	O

Further	further	O	O
studies	studies	O	O
are	are	O	O
necessary	necessary	O	O
to	to	O	O
determine	determine	O	O
the	the	O	O
exact	exact	O	O
extent	extent	O	O
of	of	O	O
this	this	O	O
problem	problem	O	O
and	and	O	O
to	to	O	O
improve	improve	O	O
the	the	O	O
efficacy	efficacy	O	O
of	of	O	O
diagnostic	diagnostic	O	O
methods	methods	O	O
.	.	O	O

